Pasireotide

CHEMBL3349607 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1047.2 g/mol

LogP

4.7

Phase

4

A somatostatin analogue with affinity for multiple somatostatin receptor subtypes, used to treat Cushing's disease and acromegaly by inhibiting ACTH and growth hormone secretion from pituitary tumors. It is more potent than octreotide at suppressing cortisol and growth hormone production.

Masse moléculaire

1047,2000 g/mol

LogP

4,70

TPSA

281,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Obesity Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O

InChI

InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1

Molecular Formula

C58H66N10O9

HBD / HBA

9 / 11

Liaisons Rotatives

18

Atomes Lourds

77

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A somatostatin analogue with affinity for multiple somatostatin receptor subtypes, used to treat Cushing's disease and acromegaly by inhibiting ACTH and growth hormone secretion from pituitary tumors. It is more potent than octreotide at suppressing cortisol and growth hormone production.

Yes, Pasireotide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3349607. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9941444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Pasireotide sur PillFYI

Structure

Données Clés

Formule: C58H66N10O9
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.